RPHM NASDAQ
Reneo Pharmaceuticals, Inc.
1W: +9.6%
1M: +27.3%
3M: +23.8%
1Y: -75.2%
3Y: -74.8%
$18.20
Last traded 2024-10-04 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$63M
-15.7% ▼
Net Income
$0
+0.0% ▲
EPS (Diluted)
$-4.40
+0.0% ▲
EBITDA
-$63M
-15.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $50K | $529K | $0 | $0 | $0 |
| Gross Profit | -$50K | -$529K | -$525K | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $28M | $38M | $56M | $44M | $48M |
| SG&A Expenses | $12M | $16M | $26M | $11M | $15M |
| Operating Expenses | $40M | $54M | $83M | $54M | $63M |
| Operating Income | -$40M | -$54M | -$83M | -$54M | -$63M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | -$300K | -$8K |
| Income Before Tax | -$40M | -$52M | -$77M | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$40M | -$50M | -$77M | $0 | $0 |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-2.19 | $-2.04 | $-2.30 | $0.00 | $-4.40 |
| EBITDA | -$40M | -$54M | -$82M | -$54M | -$63M |
| Shares Outstanding | 18M | 24M | 34M | 34M | 14M |